SERDA Therapeutics Announces Initiation of Phase 1 Clinical Study of SN514

AMSTERDAM, THE NETHERLANDS, 03 June 2024. SERDA Therapeutics, a biopharmaceutical company focused on developing improved treatments for burns and chronic wounds, today announced initiation of its first Phase 1 human clinical study of SN514 hydrogel, an innovative enzymatic wound debriding agent, in healthy adult volunteers. SN514 hydrogel is a topical debridement product designed to remove […]